Drugmaker GSK said it agreed to acquire Californian biopharmaceutical company RAPT Therapeutics RAPT0.07%increase; green up pointing triangle for around $2.2 billion, a move set to bolster its ...
This article first appeared on GuruFocus. GSK (NYSE:GSK) agreed to acquire RAPT Therapeutics (NASDAQ:RAPT) for about $2.2 billion, paying $58 a share in cash through a tender offer expected to launch ...
Stock futures edged down on Tuesday following Trump's warning of mounting tariffs on key European partners blocking a U.S. bid for Greenland control. The acquisition gives GSK global rights (excluding ...
GlaxoSmithKline (GSK) researchers at work in an R&D laboratory at the company's Stevenage, U.K., site. GSK has agreed to acquire Rapt Therapeutics for $2.2 billion, in a deal intended to bolster the ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — GSK said Tuesday it would buy RAPT Therapeutics in a deal worth ...
Hosted on MSN
Clear Street downgrades RAPT Therapeutics (RAPT)
Fintel reports that on January 20, 2026, Clear Street downgraded their outlook for RAPT Therapeutics (NasdaqGM:RAPT) from Buy to Hold. Analyst Price Forecast Suggests 9.67% Upside As of January 14, ...
Hosted on MSN
TD Cowen downgrades RAPT Therapeutics (RAPT)
Fintel reports that on January 20, 2026, TD Cowen downgraded their outlook for RAPT Therapeutics (NasdaqGM:RAPT) from Buy to Hold. Analyst Price Forecast Suggests 9.67% Upside As of January 14, 2026, ...
GSK gains global rights to ozureprubart, excluding parts of Asia RAPT's ozureprubart targets antibody causing allergic reactions Deal is GSK's first major acquisition under new CEO Luke Miels The deal ...
GSK plc (NYSE: GSK) on Tuesday agreed to acquire RAPT Therapeutics Inc. (NASDAQ: RAPT) for $58.00 per share. The deal consideration is equivalent to an estimated aggregate equity value of $2.2 billion ...
Jan 20 (Reuters) - Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat food allergies as it seeks new medicines ahead of patent ...
Investing.com -- RAPT Therapeutics Inc (NASDAQ:RAPT) stock surged 63.6% on Tuesday after pharmaceutical giant GSK plc (LON:GSK) announced plans to acquire the company for $58 per share, valuing RAPT ...
US-based biotech firm is developing treatment for allergies to nuts, milk and eggs in children and adults Business live – latest updates GSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results